Introduction Intellectual Property is a way of protecting technologically invented rights. Various forms of creation…
Renova Therapeutics(hereinafter referred as “Renova”) founded in 2009 and headquartered in San Diego, California, a biopharmaceutical company develops gene therapy treatments for congestive heart failure (CHF) and other chronic diseases The Company also provides gene therapies in pre-clinical stage for those who suffer from Type II diabetes.
Reportedly, Renova has obtained an exclusive worldwide license to a urocortin 3 gene patent from the non-profit Research Development Foundation (RDF) and plans to research this therapeutic gene with the intention to create paracrine gene therapy treatments for patients with cardiovascular diseases such as heart failure. Reportedly, previously this year only, it has also entered into a worldwide exclusive license agreement for RDF’s patent portfolio of urocortin and stresscopin genes, as well as select peptides and proteins with the intention to explore use of this family of genes to create treatment for patients suffering from cardiovascular and metabolic diseases, with one of the world’s most common, incurable and expensive chronic diseases – type 2 diabetes.
More than 28 million people globally are affected by heart failure and it is the only cardiovascular disease that is increasing in prevalence. It is the most common cause of emergency hospital admissions in patients with age 65 and older. Also, the incidence of type 2diabetes is staggering and growing rapidly, with 27.6 million people in the United States and approximately 370 million people around the world living with this debilitating disease.
This expansion of IP portfolio with RDF would permit Renova to expand inventive research in gene therapy resulting in empowerment for its paracrine gene therapy pipeline. Renova Therapeutics’ paracrine gene therapy treatments are based on a novel systemic approach that introduces therapeutic genes capable of leading the body’s cells to work more normally. This exclusive license approach exploits the use of peptide genes that possess favourable cardio-metabolic effects via their paracrine activity. This single-IV-injection treatment method is a base for future products that have the potential to fetch permanent improvements in heart failure and type 2 diabetes patients.
Definitely, patients suffering from CHS and other chronic diseases like type 2 diabetes will have profoundly positive effects on their health in near future as an outcome of Renova Therapeutics’ expansion of IP portfolio.
About the Author: Dr. Komal Tomar, Sr. Licensing Associate at IIPRD and Khurana & Khurana, Advocates and IP Attorneys and can be reached at [email protected]